AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
(pegvisomant for injection, Pharmacia)
A growth hormone receptor antagonist for acromegaly, in people who have had an inadequate response to existing treatments (surgery, radiation treatment, and other medical therapies), or when these treatments are not appropriate. The first drug in this new class of drugs to be approved.
* Recommended Dosage: Subcutaneous 40-mg loading dose, followed by a 10-mg subcutaneous injection daily, adjusting dose based on serum insulin-like growth factor-I (IGF-I) levels, with dose not to exceed 30 mg a day.
* Special Considerations: Injection site reactions, sweating, headache, and fatigue were the most common side effects associated with treatment in trials. Monitor liver function for the first 6 months of therapy; in trials, two patients (fewer than 1%) had liver function tests above 10 times the upper limit of normal.
* Comment: The goal of treatment with ...
Source: HighBeam Research, Somavert. (New & Approved: Albumin Cobalt Binding Test, Somavert).